{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-039291","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.327746+00:00","generated_at":"2026-06-15T01:20:05.331517+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BiomX Q1 net loss $6.4M; cash $30.3M; positive Part 1 BX004 data; PIPE closed","bullets":["Net loss $6.4M vs $8.2M YoY; R&D expense $4.6M; cash $30.3M as of March 31, 2023.","Positive Phase 1b/2a Part 1 BX004 results: >90% reduction in P. aeruginosa CFU; no safety events; Part 2 data expected Q3 2023.","Completed $7.5M PIPE with OrbiMed and CF Foundation; second closing in May 2023.","Jason M. Marks and Michael E. Dambach appointed to Board of Directors.","Cash runway sufficient into Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-039291","json":"https://secwatch.observer/filing/0001213900-23-039291.json","markdown":"https://secwatch.observer/filing/0001213900-23-039291.md","text":"https://secwatch.observer/filing/0001213900-23-039291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/0001213900-23-039291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/ea178578-8k_biomxinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:20:05.331517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eb425667f","claim":"Michael E. Dambach was appointed as Class II Director at BiomX Inc..","evidence_excerpt":"On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/0001213900-23-039291-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"ce380f58aa","claim":"Jason M. Marks was appointed as Class II Director at BiomX Inc..","evidence_excerpt":"On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390023039291/0001213900-23-039291-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}